{
    "clinical_study": {
        "@rank": "117744", 
        "arm_group": {
            "arm_group_label": "Trastuzumab, Capecitabine, Docetaxel", 
            "arm_group_type": "Experimental", 
            "description": "Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2  every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason."
        }, 
        "brief_summary": {
            "textblock": "Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic\n      gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease\n      are to be recruited  in the study. In the current study, the efficacy and safety of\n      Trastuzumab in combination with Capecitabine/Docetaxel will be evaluated in Chinese patients\n      with HER2 positive advanced or recurrent gastric cancer.60 patients could provide adequate\n      precision rather than controlling type I&II error. Assuming the target PFS is 6.7m, 60\n      patients will give 90% CI of (5.5, 8.4). Considering the 5% drop out rate, 65 patients will\n      be enrolled."
        }, 
        "brief_title": "Phase II Study of Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stomach Neoplasms", 
            "Neoplasms Metastasis", 
            "ERBB2 Gene Amplification"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Stomach Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase II, multi-center, open label, single arm, interventional study. Patients\n      with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma who have\n      not received prior treatment for metastatic disease will be treated with trastuzumab(8 mg/kg\n      loading dose followed by 6 mg/kg every 3 weeks ),Capecitabine(2000mg/m2d, d1-14,every 3\n      weeks) and Docetaxel (60mg/m2  every 3 weeks for 6 cycles).All patients will continue to\n      receive trastuzumab and Capecitabine until either disease progression, occurrence of\n      unacceptable toxicity or withdrawal from the study for another reason.Primary endpoints is\n      PFS and secondary endpoints are ORR, OS and Safety.Recruitment period:24 months;PFS\n      follow-up period:  80% PFS events;OS follow-up period: 18 months or 80% OS events, whichever\n      occurs first."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female. Age: 18-75 years.\n\n          2. Histologically confirmed adenocarcinoma of the stomach or gastro-esophageal junction\n             with inoperable locally advanced or recurrent and/or metastatic disease, not amenable\n             to curative therapy.\n\n          3. Measurable disease, according to the Response Evaluation Criteria in Solid Tumors\n             (RECIST) version 1.1, assessed using imaging techniques (CT or MRI).\n\n          4. HER2 positive tumor (primary tumor or metastasis, HER2 positive as defined by IHC2+\n             and a confirmatory FISH+ result (HER2:CEP17 ratio \u22652), or by an IHC 3+ result) as\n             assessed by the central laboratory. Accurate and validated assay methods will be\n             used.\n\n          5. ECOG Performance status 0-1.\n\n          6. Life expectancy of at least 3 months.\n\n          7. Signed informed consent.\n\n          8. Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant\n             therapy is allowed if at least 6 months has elapsed between completion of\n             adjuvant/neoadjuvant therapy and enrollment into the study; adjuvant/neoadjuvant\n             therapy with docetaxel is not allowed).\n\n        9 .Lack of physical integrity of the upper gastrointestinal tract or malabsorption\n        syndrome (e.g. patients with partial or total gastrectomy can enter the study, but not\n        those with a jejunostomy probe).\n\n        10. Patients with active (significant or uncontrolled) gastrointestinal bleeding.\n\n        11. Residual relevant toxicity resulting from previous therapy (with the exception of\n        alopecia), e.g. neurologic toxicity \u2265 grade 2 NCI-CTCAE version 4.0.\n\n        12. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,\n        or basal cell carcinoma.\n\n        13. Hematologic, Biochemical and Organ Function 14. Neutrophil count < 1.5 \u00d7 109/L, or\n        platelet count < 100 \u00d7 109/L. 15. Serum bilirubin > 1.5 \u00d7 upper limit of normal (ULN); or,\n        AST or ALT > 2.5 \u00d7 ULN (or > 5 \u00d7 ULN in patients with liver metastases); or, alkaline\n        phosphatase > 2.5 \u00d7 ULN (or > 5 \u00d7 ULN in patients with liver metastases, or > 10 \u00d7 ULN in\n        patients with bone but no liver metastases); or albumin < 25 g/L.\n\n        16. Creatinine clearance < 60 mL/min.\n\n        Exclusion Criteria:\n\n          1. History of documented congestive heart failure; angina pectoris requiring medication;\n             evidence of transmural myocardial infarction on ECG; poorly controlled hypertension\n             (systolic BP > 180 mmHg or diastolic BP > 100 mmHg); clinically significant valvular\n             heart disease; or high risk uncontrollable arrhythmias.\n\n          2. Baseline LVEF < 50% (measured by echocardiography or MUGA).\n\n          3. Patients with dyspnea at rest due to complications of advanced malignancy or other\n             disease, or who require supportive oxygen therapy.\n\n          4. Patients receiving chronic or high dose corticosteroid therapy. (Inhaled steroids and\n             short courses of oral steroids for anti-emesis or as an appetite stimulant are\n             allowed).\n\n          5. Known dihydropyrimidine dehydrogenase (DPD) deficiency.\n\n          6. History or clinical evidence of brain metastases.\n\n          7. Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly\n             controlled diabetes.\n\n          8. Positive serum pregnancy test in women of childbearing potential.\n\n          9. Subjects with reproductive potential not willing to use an effective method of\n             contraception.\n\n         10. Received any investigational drug treatment within 4 weeks of start of study\n             treatment.\n\n         11. Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if\n             palliative radiotherapy given to bone metastatic site peripherally and patient\n             recovered from any acute toxicity).\n\n         12. Major surgery within 4 weeks of start of study treatment, without complete recovery.\n\n         13. Patients with known active infection with HIV, HBV, or HCV.\n\n         14. Known hypersensitivity to any of the study drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004769", 
            "org_study_id": "ML28670"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trastuzumab, Capecitabine, Docetaxel", 
                "description": "Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin"
            }, 
            {
                "arm_group_label": "Trastuzumab, Capecitabine, Docetaxel", 
                "description": "Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxotere"
            }, 
            {
                "arm_group_label": "Trastuzumab, Capecitabine, Docetaxel", 
                "description": "Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Trastuzumab", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic gastric or gastro-esophageal junction cancer", 
            "Trastuzumab", 
            "HER2-positive", 
            "Capecitabine", 
            "Docetaxel", 
            "First-line therapy"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "luohy@sysucc.org.cn", 
                "last_name": "huiyan Luo, M.D,Ph.D", 
                "phone": "86-13719459226"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Medical Oncology,Sun Yat-sen University Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Ruihua Xu, M.D,Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Huiyan Luo, M.D,Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yuhong Li, M.D,Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Fenghua Wang, M.D,Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer", 
        "overall_contact": {
            "email": "xurh@sysucc.org.cn", 
            "last_name": "Ruihua Xu, M.D,PH.D", 
            "phone": "8613922206676"
        }, 
        "overall_contact_backup": {
            "email": "luohy@sysucc.org.cn", 
            "last_name": "Huiyan Luo, M.D,PH.D", 
            "phone": "8613719459226"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Ruihua Xu, M.D,Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The PFS was calculated from the initiation of chemotherapy to the date of disease progression or death,", 
            "measure": "PFS(Progression-free survival )", 
            "safety_issue": "No", 
            "time_frame": "80% PFS events;"
        }, 
        "reference": [
            {
                "PMID": "9563897", 
                "citation": "Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998 Apr;4(4):1013-9."
            }, 
            {
                "PMID": "20728210", 
                "citation": "Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, R\u00fcschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19."
            }, 
            {
                "PMID": "17664469", 
                "citation": "Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23."
            }, 
            {
                "PMID": "15659494", 
                "citation": "Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol. 2005 Jan 20;23(3):494-501."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004769"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Ruihua Xu", 
            "investigator_title": "Vice-president and Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall tumor response: This is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response as determined by the RECIST criteria from confirmed radiographic evaluations of target and non-target lesions.", 
                "measure": "ORR (Overall tumor response)", 
                "safety_issue": "Yes", 
                "time_frame": "80% PFS events;"
            }, 
            {
                "description": "Overall survival was measured from the initiation of chemotherapy to the date of the last follow-up or death.", 
                "measure": "OS (Overall survival )", 
                "safety_issue": "No", 
                "time_frame": "OS follow-up period: 18 months or 80% OS events, whichever occurs first."
            }, 
            {
                "description": "Adverse events and laboratory tests graded according to the NCI-CTC AE Version 4.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "AEs (Adverse events) should be recorded during the study period and six months after last IMP administration"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Fudan University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "307 Hospital of PLA", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong Tumor Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tongji Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "West China Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Shandong Provincial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Second Affiliated Hospital of Suzhou University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Tianjin Medical University General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Second Affiliated Hospital, School of Medicine, Zhejiang University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Sixth Affiliated Hospital, Sun Yat-sen University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Nanfang Hospital of Southern Medical University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}